ITIchiro Tanaka

Ichiro Tanaka

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ichiro Tanaka has a total of 55 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Support for patients with hemophilia affected by the Great East Japan Earthquake

    by Ichiro Tanaka, Kagehiro Amano, Masashi Taki, Toshiaki Oka, Michio Sakai, Midori Shima, Akira Shirahata, Hideyuki Takedani, Hideji Hanabusa, Satoshi Higasa, et al.

    総合学術電子ジャーナルサイト「J-STAGE」-国内で発行された学術論文全文を読むことのできる、日本最大級の総合電子ジャーナルプラットフォームです。

  • Open Access

    Current use of bypassing agents in Japan in patients with congenital hemophilia and inhibitors

    by Ichiro Tanaka, Kagehiro Amano, Masashi Taki, Toshiaki Oka, Michio Sakai, Akira Sirahata, Noboru Takata, Junki Takamatsu, Hideyuki Taketani, Hideji Hanabusa, et al.

    わが国におけるインヒビター保有先天性血友病患者に対するバイパス止血療法の現状と問題点を探る目的で,国内の代表的な血友病診療施設9施設にアンケート調査を行った.調査内容はインヒビター治療製剤の選択の他,バイパス止血製剤の投与方法や保険適応外使用,モニタリング検査,副作用などであった.このうち,治療製剤選択に関する設問では5 Bethesda単位(BU)/ml未満のローレスポンダーおよび現在5 BU/ml未満,5-10 BU/ml,10 BU/ml超のハイレスポンダーの4つの場合に分けて,それぞれ軽度出血,重度出血および手術時における製剤選択について質問した.その結果,5 BU/ml未満のローレスポンダーの軽度出血時および現在5 BU/ml未満のハイレスポンダーの重度出血や手術時において,バイパス止血療法を選択するのか,インヒビター中和療法を選択するのかで意見が分かれた.今後,わが国のガイドラインを作成するにあたり,これらの意見を集約していく必要がある.

  • Highly Conserved Antigenic Structure of the Factor VIII C2 Domain in Some Mammals

    by Jun-Ichi Ori, Ichiro Tanaka, Yoko Kubota, Midori Shima, Tomoko Matsumoto, Koichi Yoshida, Yoshihiko Sakurai, Akira Yoshioka

    To elucidate differences in the antigenic structure of factor VIII (FVIII) among mammals, we evaluated cross-reactivities of well-defined antihuman FVIII antibodies with canine and other mammalian FVIII proteins. Monoclonal antibodies against human FVIII recognizing the A1 domain in the heavy chain and the A3 domain in the light chain showed 2.7% and 0% crossreactivities, respectively, with canine FVIII. The cross-reactivities of 2 alloantibodies and a monoclonal antibody that recognized the A2 domain in the heavy chain were 10%, 38%, and 0%, respectively. On the other hand, 2 kinds of alloantibodies and a monoclonal antibody recognizing the C2 domain in the light chain showed 160%, 390%, and 130% cross-reactivity, respectively, with canine FVIII. The anti-C2 monoclonal antibody (NMC-VIII/5) showed a type 2 inactivating property when tested with canine and human plasma. Moreover, cross-reactivities of NMC-VIII/5 with simian and feline FVIII were 54.5% and 82.8%, respectively, while the cross-reactivities of the anti-A2 monoclonal antibody (JR8) with simian and feline FVIII were 1.3% and 0%, respectively. These findings suggest that the antigenic structure of the C2 epitope has remained relatively conserved throughout mammalian evolution in contrast to the A2 epitope and that a canine model of hemophilia A is useful for FVIII inhibitor experiments.


  • Unresponsiveness to factor VIII inhibitor bypassing agents during haemostatic treatment for life‐threatening massive bleeding in a patient with haemophilia A and a high responding inhibitor

    by T. Hayashi, I. Tanaka, M. Shima, K. Yoshida, K. Fukuda, Y. Sakurai, T. Matsumoto, J. C. Giddings, A. Yoshioka

    Summary. We report a case of haemophilia A with a high responding inhibitor of factor VIII (FVIII) who had a serious retroperitoneal haematoma caused by penetration of a duodenal ulcer. Inhibitor‐bypassing therapy was commenced immediately on admission. On the 17th day of treatment with activated prothrombin complex concentrate (APCC; FEIBA®), re‐bleeding occurred and thrombelastography (TEG) demonstrated resistance to therapy. Treatment was changed to recombinant activated factor VII (rFVIIa; NovoSeven®) and resulted in clinical improvement together with an improvement in TEG parameters. On the 10th day of continuous infusion with NovoSeven®, however, TEG again showed resistance to therapy. FEIBA® infusions were re‐introduced and TEG results remained satisfactory for 7 days. On day 34, however, further retroperitoneal bleeding was evident and a decline in the haemostatic efficiency of FEIBA® was recorded by TEG. NovoSeven® was again successfully administered for 7 days. There were no laboratory findings to indicate disseminated intravascular coagulation (DIC), hypercoagulability or abnormal fibrinolysis. The plasma‐based clotting tests did not show any additional prolongation on the occasions when the TEG demonstrated unresponsiveness to FEIBA® or NovoSeven®. These findings suggested that some component of whole blood, other than plasma might have governed the TEG data. The long‐term use of APCC such as FEIBA® or rFVIIa, requires careful monitoring in terms of FVIII inhibitor bypassing activity as well as the tendency to DIC.


  • Effectiveness of factor VIII infusions in haemophilia A patients with high responding inhibitors

    by S. Kasuda, I. Tanaka, M. Shima, T. Matsumoto, Y. Sakurai, K. Nishiya, A. R. Giles, A. Yoshioka

    We report here the efficacy of factor VIII (FVIII) infusions in two haemophiliacs with inhibitors using clot waveform analysis on the MDA II system, which was possible to detect very low levels of FVIII activity < 1.0 U dL(-1). In the presence of type 1 inhibitors at the level of 6.2 (patient 1) and 14.4 (patient 2) Bethesda Units mL(-1), 3.2 and 6.5 U dL(-1) of FVIII:C remained 30 min after the infusion of FVIII (100 U kg(-1)), respectively. Moreover, 0.9 U dL(-1) of FVIII:C remained 24 h after infusion in patient 2. In both cases, these changes were reflected by qualitative improvement in the aPTT clot waveform and quantitative changes in the minimum value of the second derivative of the aPTT waveform (Min2) that reflects clot acceleration. These results suggest that FVIII infusion may be continued with clinical benefit in some haemophiliacs with high responding inhibitors. Furthermore, the haemostatic response may be monitored accurately and efficiently by clot waveform analysis.


    • 1 June 2004
      • Vol. 89  (6) , 696-703

    Association of anti-idiotypic antibodies with immune tolerance induction for the treatment of hemophilia A with inhibitors.

    by Yoshihiko Sakurai, Midori Shima, Ichiro Tanaka, Kazuyoshi Fukuda, Koichi Yoshida, Akira Yoshioka

    Hemophilia A patients with inhibitors can be treated effectively with immune tolerance induction therapy (ITI). One of the underlying mechanisms of ITI is conceived to be a neutralizing activity of anti-idiotypic antibodies on inhibitors. The goal of the present study was to develop an uncomplicated method for assessing antiidiotypic antibodies and to prove the advent of anti-idiotypic antibodies in ITI. We studied a total of 26 plasma samples obtained from 9 hemophilic inhibitor patients who were treated with ITI. The samples were investigated with a novel method for detecting anti-idiotypic antibodies based on a liquid phase blocking immunoprecipitation. Plasma anti-factor VIII (FVIII) antibody titer was reduced by adding plasma from patients who had received completely successful ITI. This anti-FVIII antibody-neutralization activity of the plasma was impaired by treating the plasma with protein G beads. In addition, treating inhibitor plasma from patients in whom ITI had been unsuccessful with FVIII affinity beads resulted in the development of the anti-FVIII antibody-neutralization activity. Furthermore, the anti-FVIII antibody-neutralization activity of anti-FVIII antibody-depleted plasma obtained in a late period of ITI on inhibitor plasmas obtained during ITI increased over time. Our results suggest that; (i) plasma from patients in whom ITI was completely successful contained an anti-FVIII antibody-neutralization factor; (ii) the anti-FVIII antibody-neutralization factor was in the IgG fraction (i.e., the factor would be anti-idiotypic antibodies), and (iii) anti-idiotypic antibodies existed even in plasma from patients in whom ITI was unsuccessful. Our observations support the notion that the mechanism of ITI is associated with the development of anti-idiotypic antibodies.


  • An Alloantibody Recognizing the FVIII A1 Domain in a Patient with CRM Reduced Haemophilia A due to Deletion of a Large Portion of the A1 Domain DNA Sequence

    by Masaru Shibata, Shogo Morichika, John McVey, Edward G. D. Tuddenham, Ichiro Tanaka, Hiroshi Suzuki, Keiji Nogami, Yohko Minamoto, Takaaki Hato, Evgueni L. Saenko, et al.

    We report the development of a FVIII inhibitor in a patient with severe, cross reacting material reduced (CRMR) haemophilia A. The level of Factor VIII antigen (FVIII:Ag) measured by ELISA using anti- C2 monoclonal and alloantibodies was 1.9 U/dl. This baseline FVIII:Ag level was increased to 8.3 U/dl after administration of DDAVP. The anti-FVIII inhibitor titer was 2.9 Bethesda U/ml. DNA analysis showed a large deletion of the FVIII gene from exon 4 to 7, corresponding to amino acid residues 111-317 included within the A1 domain. The size of the gene deletion was approximately 28 kb. 5' and 3' breakpoints were identified by sequencing in intron 3 and intron 7, respectively. FVIII mRNA was detected in the patient’s peripheral lymphocytes and the deletion spanning exon 4 to 7 was confirmed at the RNA level. Immunoprecipitation experiments using 125I labeled A1, A2 and light chain demonstrated that the inhibitor reacted only with the 54 kDa A1 domain. The inhibitor activity was more than 95% neutralized by A1 domain polypeptide. Our findings suggest a close relationship between the inhibitor epitope and the specific gene deletion with regard to the pathogenesis of the inhibitor in this patient.


  • Enzyme-linked immunosorbent assay (ELISA) of factor VIII antigen using a monoclonal antibody devoid of factor VIII inhibitor activity.

    by Midori Shima, Akira Yoshioka, Ichiro Tanaka, Toshiharu Fujiwara, Shunsuke Imai, Yoshihiko Tsubura, Hiromu Fukui